U.S. markets closed
  • S&P 500

    4,280.15
    +72.88 (+1.73%)
     
  • Dow 30

    33,761.05
    +424.35 (+1.27%)
     
  • Nasdaq

    13,047.19
    +267.29 (+2.09%)
     
  • Russell 2000

    2,016.62
    +41.36 (+2.09%)
     
  • Crude Oil

    91.88
    -0.21 (-0.23%)
     
  • Gold

    1,818.90
    +3.40 (+0.19%)
     
  • Silver

    20.83
    +0.14 (+0.66%)
     
  • EUR/USD

    1.0260
    -0.0066 (-0.64%)
     
  • 10-Yr Bond

    2.8490
    -0.0390 (-1.35%)
     
  • GBP/USD

    1.2141
    -0.0061 (-0.50%)
     
  • USD/JPY

    133.4560
    +0.4570 (+0.34%)
     
  • BTC-USD

    24,386.22
    -143.88 (-0.59%)
     
  • CMC Crypto 200

    574.64
    +3.36 (+0.59%)
     
  • FTSE 100

    7,500.89
    +34.98 (+0.47%)
     
  • Nikkei 225

    28,546.98
    +727.68 (+2.62%)
     

Verona Pharma to Present at H.C. Wainwright BioConnect Virtual Conference

  • Oops!
    Something went wrong.
    Please try again later.
·2 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

LONDON and RALEIGH, N.C., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that David Zaccardelli, Pharm. D., President and Chief Executive Officer, will present a company overview at the H.C. Wainwright BioConnect Virtual Conference. The presentation will be available on-demand starting at 7:00 AM EST / 12:00 PM GMT on Monday, January 10, 2022.

A webcast of the event will be available for 90 days on the Events and Presentations link on the Investors page of the Company’s website, www.veronapharma.com.

For further information please contact:

Verona Pharma plc

US Tel: +1-833-417-0262
UK Tel: +44 (0)203 283 4200

Victoria Stewart, Director of Investor Relations and Communications

info@veronapharma.com

Argot Partners
(US Investor Enquiries)

Tel: +1-212-600-1902
verona@argotpartners.com

Kimberly Minarovich / Michael Barron

Optimum Strategic Communications
(International Media and European Investor Enquiries)

Tel: +44 (0)203 950 9144
verona@optimumcomms.com

Mary Clark / Stella Lempidaki / Zoe Bolt

About Verona Pharma

Verona Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of respiratory diseases with significant unmet medical needs. If successfully developed and approved, Verona Pharma’s product candidate, ensifentrine, has the potential to be the first therapy for the treatment of respiratory diseases that combines bronchodilator and anti-inflammatory activities in one compound. The Company is evaluating nebulized ensifentrine in its Phase 3 clinical program ENHANCE (“Ensifentrine as a Novel inHAled Nebulized COPD thErapy”) for COPD maintenance treatment. Two additional formulations of ensifentrine are in Phase 2 development for the treatment of COPD: dry powder inhaler (“DPI”) and pressurized metered-dose inhaler (“pMDI”). Ensifentrine has potential applications in cystic fibrosis, asthma and other respiratory diseases. For more information, please visit www.veronapharma.com.